HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
11.45
+0.22 (1.96%)
May 29, 2026, 4:00 PM EDT - Market closed
HUTCHMED (China) Revenue
In the year 2025, HUTCHMED (China) had annual revenue of $548.51M, down -12.96%. HUTCHMED (China) had revenue of $270.84M in the half year ending December 31, 2025, a decrease of -11.24%.
Revenue (ttm)
$548.51M
Revenue Growth
-12.96%
P/S Ratio
3.70
Revenue / Employee
$305,408
Employees
1,796
Market Cap
2.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 548.51M | -81.69M | -12.96% |
| Dec 31, 2024 | 630.20M | -207.80M | -24.80% |
| Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
| Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
| Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
| Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
| Dec 31, 2019 | 204.89M | -9.22M | -4.31% |
| Dec 31, 2018 | 214.11M | -27.09M | -11.23% |
| Dec 31, 2017 | 241.20M | 25.12M | 11.63% |
| Dec 31, 2016 | 216.08M | 37.88M | 21.25% |
| Dec 31, 2015 | 178.20M | 90.87M | 104.06% |
| Dec 31, 2014 | 87.33M | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.53B |
| Perrigo Company | 4.18B |
| Phibro Animal Health | 1.50B |
| Prestige Consumer Healthcare | 1.09B |
| ANI Pharmaceuticals | 923.71M |
| BioCryst Pharmaceuticals | 885.72M |
| Evotec SE | 859.03M |
| Supernus Pharmaceuticals | 776.83M |
HCM News
- 2 days ago - A Look at HUTCHMED (China) Ltd (HCM) After 4.3% Decline -- GF Value $13.82 vs Price $11.22 - GuruFocus
- 2 days ago - Hutchmed upgraded to Equal Weight from Underweight at Morgan Stanley - TheFly
- 9 days ago - HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting - GlobeNewsWire
- 9 days ago - Hutchmed And Innovent Secure NMPA Approval For ELUNATE-TYVYT Combo In Advanced Renal Cell Carcinoma - Nasdaq
- 9 days ago - HCM Receives Approval for New Cancer Treatment in China - GuruFocus
- 9 days ago - Hutchmed, Innovent jointly announce NMPA approval for Elunate/Tyvyt combination - TheFly
- 9 days ago - Hutchmed, Innovent Biologics announce China NMPA approval for NDA - TheFly
- 9 days ago - HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma - GlobeNewsWire